980 
Swedish healthcare organisations, the Regional Cancercentrum Stockholm – Gotland (RCC) and Karolinska University Hospital (Karolinska) have signed a deal with RxEye, a leading cloud-based solution provider to enable diagnostic imaging networks, to roll out Silverlink Software’s Multi-Disciplinary Treatment Management (MDTM) solution, to improve outcomes in patients with colorectal cancer.
Colorectal cancer is the third most common cancer in the world, and is most prevalent in developed countries, especially those in the Nordic region. RCC together with Karolinska is one of six regional cancer centres that provide clinical guidelines, healthcare processes, best practice and drug regime information to improve cancer care in accordance with the country’s National Cancer Strategy.
Karolinska are using Silverlink’s MDTM solution as a component RxEye’s Cloud Platform to enable the exchange of patient information and collaboration between multidisciplinary teams in real-time and from any location. In an effort to continue to improve and streamline the colorectal cancer pathway, the organisations collectively sought out a solution that facilitated point-of-care data insights and ensure that key clinical information was captured from initial diagnosis through to treatment and follow up.
“MDTM is a crucial clinical component in delivering cancer care because it contains a single view of all the clinical information necessary to create individual treatment plans for the patient. The Silverlink solution delivered as part of the RxEye Collaboration platform will enable the region to conduct more effective MDTMs and improve patient outcomes,” said Dr Christina Kling-Hassler, Senior Advisor and Programme Manager at Regionalt Cancercentrum Stockholm-Gotland.
Silverlink has a proven track record of creating products that improve the diagnosis, treatment and follow up of patients throughout the UK. Silverlink’s MDTM solution is a module of the wider CancerPlan product, a complete data capturing and patient monitoring system. MDTM provides clinicians with a comprehensive overview of individual patients, thereby improving communication, decision making and patient centered care.
There are plans to extend the products capabilities and implement it in additional sites in Sweden and in the Nordic countries over the coming months.
“We are excited about the collaboration with Silverlink to dramatically improve cancer outcomes in the country,” said RxEye Operations Director, Magnus Hök. “RxEye’s solution is designed to facilitate communication between all the clinicians involved in delivering cancer treatment, we’re very pleased to extend that offering to empower and enable clinically relevant, data based, collaborative decision-making.”
In conjunction with the role out of the MDTM management solution to optimise and streamline the colorectal cancer pathway at additional sites, the organisations have collectively begun identifying use of the solution to encompass multiple tumour types across treatment centres throughout the Nordic region.
“This collaboration is the start of true connected care in the region and we’re glad to be a part of the transformation. We’re confident that we can demonstrate how accessible, intelligent data can improve cancer treatment for the patient and the care team simultaneously,” said Silverlink’s CancerPlan Product Manager, Rob Dixon.
